Jiangsu Vcare Closes Series A2 Financing
Published Time:
2022-05-06 17:26
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
Currently, Jiangsu Vcare’s innovative drug pipeline is advancing steadily, with multiple drug candidates progressing through key stages. In 2022, several programs reached critical milestones:Vicagrel, a new cardiovascular and cerebrovascular drug (targeting P2Y12), obtained clinical approval from the US FDA. The drug has already initiated Phase III clinical research in China, with a research protocol that meets the requirements for both Chinese and US filings, and the US clinical trial is about to start; VC004, an anti-tumor new drug (targeting NTRK), has enrolled multiple patients in its Ib trial with significant efficacy, and the US IND application is soon to be submitted; VC005, a highly selective JAK1 inhibitor, is about to complete the SAD study, showing favorable preliminary safety and PK-PD properties. Additionally, nearly ten innovative drug candidates are in active development. The company’s wholly-owned subsidiary, Nanjing Vcare Pharmatech Co., Ltd. , continues to enhance its integrated CRO/CDMO services. Its Phase II CDMO R&D Technology Center is nearing completion, and the acquisition and construction of CDMO manufacturing facilities are progressing rapidly. With investor support, Jiangsu Vcare will accelerate its dual-track strategy: advancing proprietary drug development while expanding comprehensive drug industry chain services.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We are honored by the continued trust of our existing shareholders and deeply grateful for the recognition from new investors. Together, we will integrate resources to empower Vcare’s growth, accelerating the development of our integrated CRO/CDMO platform. We are proud to contribute our team’s decades of industry expertise, innovative technologies, internationally compliant manufacturing controls, and commitment to green chemistry principles to China’s dynamic and innovative pharmaceutical sector. This collaboration will strengthen China’s pharmaceutical supply chain, accelerate global integration, and deliver sustainable long-term value for our shareholders."
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn